Besides, comprehensive analysis indicated that the key m6A regulator, HNRNPC, is not only a novel prognostic biomarker in multiple cancers, but also regulates tumor immune microenvironment and immune checkpoints, providing a vital opportunity for developing immune targets. The gene discussed is HNRNPC; the disease is neoplasm.